NZ591922A - High affinity human antibodies to human il-4 receptor - Google Patents

High affinity human antibodies to human il-4 receptor

Info

Publication number
NZ591922A
NZ591922A NZ591922A NZ59192209A NZ591922A NZ 591922 A NZ591922 A NZ 591922A NZ 591922 A NZ591922 A NZ 591922A NZ 59192209 A NZ59192209 A NZ 59192209A NZ 591922 A NZ591922 A NZ 591922A
Authority
NZ
New Zealand
Prior art keywords
antibody
seq
antigen
hll
binding fragment
Prior art date
Application number
NZ591922A
Other languages
English (en)
Inventor
Joel H Martin
Tammy T Huang
Jeanette L Fairhurst
Nicholas J Papadopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41600767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ591922(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority to NZ596093A priority Critical patent/NZ596093A/xx
Publication of NZ591922A publication Critical patent/NZ591922A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
NZ591922A 2008-10-29 2009-10-27 High affinity human antibodies to human il-4 receptor NZ591922A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ596093A NZ596093A (en) 2008-10-29 2009-10-27 High affinity human antibodies to human il-4 receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/260,307 US7608693B2 (en) 2006-10-02 2008-10-29 High affinity human antibodies to human IL-4 receptor
PCT/US2009/062168 WO2010053751A1 (en) 2008-10-29 2009-10-27 High affinity human antibodies to human il-4 receptor

Publications (1)

Publication Number Publication Date
NZ591922A true NZ591922A (en) 2012-03-30

Family

ID=41600767

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ591922A NZ591922A (en) 2008-10-29 2009-10-27 High affinity human antibodies to human il-4 receptor
NZ596093A NZ596093A (en) 2008-10-29 2009-10-27 High affinity human antibodies to human il-4 receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ596093A NZ596093A (en) 2008-10-29 2009-10-27 High affinity human antibodies to human il-4 receptor

Country Status (47)

Country Link
US (7) US7608693B2 (enExample)
EP (7) EP3064511B1 (enExample)
JP (8) JP5291802B2 (enExample)
KR (1) KR101599706B1 (enExample)
CN (3) CN103739711B (enExample)
AR (1) AR073978A1 (enExample)
AU (1) AU2009311496B9 (enExample)
BR (1) BRPI0919853B8 (enExample)
CA (1) CA2737044C (enExample)
CL (1) CL2009002004A1 (enExample)
CO (1) CO6362024A2 (enExample)
CR (1) CR20110148A (enExample)
CY (3) CY1114123T1 (enExample)
DK (3) DK3064511T3 (enExample)
EC (1) ECSP11011010A (enExample)
ES (4) ES2675917T3 (enExample)
FI (1) FI3715372T3 (enExample)
FR (1) FR18C1011I2 (enExample)
HN (1) HN2011001210A (enExample)
HR (3) HRP20240492T1 (enExample)
HU (3) HUS1800014I1 (enExample)
IL (1) IL211726A (enExample)
JO (1) JO2865B1 (enExample)
LT (3) LT3715372T (enExample)
LU (1) LUC00059I2 (enExample)
MA (1) MA32802B1 (enExample)
MX (3) MX356882B (enExample)
MY (1) MY152448A (enExample)
NI (1) NI201100064A (enExample)
NL (1) NL300922I2 (enExample)
NO (2) NO2018009I2 (enExample)
NZ (2) NZ591922A (enExample)
PA (1) PA8847001A1 (enExample)
PE (1) PE20100738A1 (enExample)
PH (1) PH12014500462A1 (enExample)
PL (4) PL3064511T3 (enExample)
PT (4) PT3715372T (enExample)
RS (3) RS65385B1 (enExample)
RU (2) RU2539774C3 (enExample)
SI (3) SI3064511T1 (enExample)
SM (2) SMT201800362T1 (enExample)
SV (1) SV2011003880A (enExample)
TW (3) TWI538686B (enExample)
UA (1) UA102122C2 (enExample)
UY (1) UY32213A (enExample)
WO (1) WO2010053751A1 (enExample)
ZA (1) ZA201101867B (enExample)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1741783A4 (en) * 2004-04-27 2009-05-27 Chemo Sero Therapeut Res Inst HUMAN ANTIAMYLOID BETA PEPTIDE ANTIBODY AND ANTIBODY FRAGMENT THEREOF
EP2769992B1 (en) * 2006-10-02 2020-12-30 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
NZ631363A (en) 2010-02-08 2016-05-27 Regeneron Pharma Common light chain mouse
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
UA111731C2 (uk) * 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
WO2012047954A1 (en) * 2010-10-06 2012-04-12 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
SI2668212T1 (en) 2011-01-28 2018-08-31 Sanofi Biotechnology, Human antibodies against PCSK9 for use in the treatment processes of certain groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
DK2739740T3 (da) 2011-08-05 2019-12-09 Regeneron Pharma Universelle, humaniserede letkæde-mus
AU2012308797B2 (en) 2011-09-16 2017-06-01 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9)
AR089425A1 (es) * 2011-12-22 2014-08-20 Astellas Pharma Inc Anticuerpo ctgf (factor de crecimiento de tejido conectivo) antihumano
PT2825036T (pt) 2012-03-16 2018-07-26 Regeneron Pharma Anticorpos de cadeia leve manipulados em histidina e roedores geneticamente modificados para gerar os mesmos
NZ629077A (en) 2012-03-16 2015-12-24 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
ES2701093T3 (es) 2012-08-21 2019-02-20 Sanofi Biotechnology Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
PT2888281T (pt) * 2012-08-21 2018-12-14 Regeneron Pharma Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r
SG10201913822PA (en) * 2012-09-07 2020-03-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
NZ731864A (en) * 2012-09-07 2022-07-01 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI633891B (zh) * 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
ES2747630T3 (es) * 2013-06-21 2020-03-11 Sanofi Biotechnology Métodos de tratamiento de poliposis nasal administrando un antagonista de IL-4R
SI3010539T1 (sl) 2013-06-21 2019-11-29 Regeneron Pharma Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
EP3094644B1 (en) * 2014-01-16 2019-07-24 Mondelli, Mario Umberto Franceso Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
IL247290B (en) * 2014-02-21 2021-06-30 Sanofi Biotechnology Methods of treating or preventing asthma by adding an il-4r antagonist
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
EP4353254A3 (en) 2014-02-28 2024-07-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
NO2785538T3 (enExample) * 2014-05-07 2018-08-04
CN107206068A (zh) 2014-07-16 2017-09-26 赛诺菲生物技术公司 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法
MX2017006286A (es) 2014-11-14 2018-01-23 Sanofi Biotechnology Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
CN107683291B (zh) 2015-04-02 2021-11-19 英特维特国际股份有限公司 针对犬白介素-4受体α的抗体
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR20180034672A (ko) 2015-08-18 2018-04-04 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
CA3014202A1 (en) 2016-02-19 2017-08-24 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
CN107474134B (zh) * 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
MX2019002344A (es) 2016-09-01 2019-09-06 Regeneron Pharma Metodos de prevenir o tratar la alergia administrando un antagonista de il-4r.
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
RU2759630C2 (ru) 2016-09-22 2021-11-16 Ридженерон Фармасьютикалз, Инк. Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
JP7174699B2 (ja) 2016-11-29 2022-11-17 レゲネロン ファーマシューティカルス，インコーポレーテッド Ｐｒｌｒ陽性乳癌の治療方法
TWI857389B (zh) * 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
KR102751957B1 (ko) 2017-04-13 2025-01-09 리제너론 파마슈티칼스 인코포레이티드 Il33 및 il1rl1을 코딩하는 유전자에서의 위험 대립유전자를 갖는 환자에서의 폐 질환의 치료 및 저해
AU2018298039B2 (en) 2017-07-06 2023-02-02 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
JP7315545B2 (ja) 2017-10-30 2023-07-26 サノフィ・バイオテクノロジー Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
AU2018392334A1 (en) 2017-12-22 2020-05-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
SG11202005235WA (en) 2018-01-31 2020-07-29 Regeneron Pharma System and method for characterizing size and charge variant drug product impurities
WO2019148405A1 (zh) * 2018-02-01 2019-08-08 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
CN113150146B (zh) * 2018-02-01 2022-07-12 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
CN111771000A (zh) 2018-02-28 2020-10-13 瑞泽恩制药公司 用于鉴定病毒污染物的系统和方法
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
WO2019182901A1 (en) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
KR20250160366A (ko) 2018-03-22 2025-11-12 서피스 온콜로지, 엘엘씨 항-il-27 항체 및 이의 용도
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
BR112020020387A2 (pt) 2018-05-13 2021-01-19 Regeneron Pharmaceuticals, Inc. Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r
CN113101364B (zh) * 2018-05-29 2023-12-01 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制剂的开发和应用
CA3104873A1 (en) 2018-07-10 2020-01-16 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-existing interactions
EP3808774B1 (en) 2018-08-24 2025-04-16 Jiangsu Hengrui Medicine Co., Ltd. Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
US11754569B2 (en) 2018-08-30 2023-09-12 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CN110872349A (zh) 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
WO2020096381A1 (ko) * 2018-11-09 2020-05-14 아주대학교 산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
EP3857236A1 (en) 2019-01-16 2021-08-04 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
MA55204A (fr) 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
KR20220007586A (ko) 2019-05-13 2022-01-18 리제너론 파마슈티칼스 인코포레이티드 개선된 경쟁적 리간드 결합 검정
CN111592597B (zh) * 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
EP3999114A1 (en) 2019-07-16 2022-05-25 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US12090201B2 (en) 2019-08-05 2024-09-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody
WO2021026203A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
IL317159A (en) 2019-09-24 2025-01-01 Regeneron Pharma Systems and methods for use in chromatography and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
CN114760986A (zh) 2019-11-25 2022-07-15 里珍纳龙药品有限公司 使用非水性乳液的持续释放调配物
EP4073810A1 (en) 2019-12-09 2022-10-19 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
MX2022008973A (es) 2020-01-21 2022-08-11 Regeneron Pharma Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
MX2022010217A (es) 2020-02-21 2022-09-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma.
JP7711079B2 (ja) * 2020-02-27 2025-07-22 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｉｌ４ｒに結合する抗体とその使用
CN115427450A (zh) 2020-03-27 2022-12-02 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
CN113549151A (zh) * 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
US20250154267A2 (en) 2020-05-22 2025-05-15 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
WO2022047108A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
CA3194111A1 (en) 2020-10-05 2022-04-14 Christine XU Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
US12239687B2 (en) 2020-11-25 2025-03-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
US20240075158A1 (en) 2020-12-22 2024-03-07 Jiangsu Hengrui Pharmaceutical Co., Ltd. Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof
CA3204515A1 (en) 2021-01-08 2022-07-14 Jamie M. Orengo Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
CA3202197A1 (en) 2021-01-20 2022-07-28 Reginald Smith Methods of improving protein titer in cell culture
EP4302098A1 (en) 2021-03-03 2024-01-10 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
EP4315344A1 (en) 2021-03-26 2024-02-07 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
CA3220848A1 (en) 2021-06-01 2022-12-08 Timothy Riehlman Microchip capillary electrophoresis assays and reagents
IL310362A (en) 2021-07-26 2024-03-01 Sanofi Biotechnology Methods for the treatment of chronic spontaneous urticaria by administration of an IL-4R antagonist
TWI876192B (zh) * 2021-08-05 2025-03-11 美商美國禮來大藥廠 人類介白素-4受體α抗體
JP2024530954A (ja) 2021-08-10 2024-08-27 カイマブ・リミテッド アトピー性皮膚炎の処置
WO2023028468A1 (en) 2021-08-23 2023-03-02 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
JP2024531353A (ja) * 2021-08-26 2024-08-29 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 抗ｉｌ４ｒ抗体の医薬組成物及びその使用
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
US20230090912A1 (en) * 2021-09-20 2023-03-23 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
US20230151426A1 (en) 2021-09-30 2023-05-18 Regeneron Pharmaceuticals, Inc. Reticulocalbin-3 (RCN3) Variants And Treatment Of Asthma With Interleukin-4 Receptor Alpha (IL4R) Antagonists
US20230116199A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
IL311248A (en) 2021-10-07 2024-05-01 Regeneron Pharma PH meter calibration and repair
CN119137149A (zh) 2021-10-20 2024-12-13 赛诺菲生物技术公司 用于通过施用il-4r拮抗剂来治疗结节性痒疹的方法
KR20240097864A (ko) 2021-10-26 2024-06-27 리제너론 파마슈티칼스 인코포레이티드 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법
JP2024544855A (ja) 2021-11-11 2024-12-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド インターロイキン３３（ｉｌ－３３）の多遺伝子リスクスコアの層別化に基づく肺疾患の処置
WO2023085978A1 (en) * 2021-11-11 2023-05-19 Joint Stock Company «Biocad» Monoclonal antibody or antigen-binding fragment thereof that specifically binds to il-4ra, and use thereof
JP2024542194A (ja) * 2021-11-18 2024-11-13 ツイスト バイオサイエンス コーポレーション Ｄｉｃｋｋｏｐｆ－１バリアント抗体及び使用方法
CN118215747A (zh) 2021-11-30 2024-06-18 雷杰纳荣制药公司 基于与对治疗剂的反应相关的多基因得分的分层对肺疾病进行的治疗
CA3241374A1 (en) 2021-12-30 2023-07-06 Gregory GEBA Methods for attenuating atopic march by administering an il-4/il-13 antagonist
CA3248953A1 (en) 2022-01-29 2025-01-16 Jiangsu Hengrui Pharmaceuticals Co Ltd GLUCOCORTICOID MEDICINE CONJUGATE
EP4486778A1 (en) 2022-03-02 2025-01-08 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023191665A1 (en) * 2022-03-31 2023-10-05 Milaboratory, Limited Liability Company ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF
TW202421660A (zh) 2022-07-08 2024-06-01 美商再生元醫藥公司 藉由投與il-4r拮抗劑來治療嗜伊紅性食道炎的方法
JP2025528456A (ja) 2022-08-29 2025-08-28 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストの投与による慢性誘発性寒冷蕁麻疹の治療方法
KR20240038841A (ko) 2022-09-16 2024-03-26 연세대학교 산학협력단 신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이의 용도
IL320362A (en) 2022-11-01 2025-06-01 Regeneron Pharma Methods for treating hand and foot skin infections by administering an IL-4R antagonist
WO2024112935A1 (en) 2022-11-23 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for improving bone growth by administering an il-4r antagonist
KR20250124178A (ko) 2022-12-16 2025-08-19 리제너론 파아마슈티컬스, 인크. 크로마토그래피 칼럼의 무결성을 평가하기 위한 방법 및 시스템
US20240248097A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
TW202445135A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 液態蛋白質組成物穩定性之建模方法
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
AU2024221322A1 (en) * 2023-02-17 2025-07-03 Apogee Therapeutics, Inc. Antibodies that bind interleukin 4 receptor alpha and methods of use
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
WO2024197119A1 (en) 2023-03-22 2024-09-26 Sanofi Biotechnology Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
CN121001741A (zh) 2023-03-27 2025-11-21 瑞泽恩制药公司 用于通过施用il-4r拮抗剂治疗嗜酸粒细胞性胃肠炎的方法
WO2024199665A1 (en) 2023-03-30 2024-10-03 Sandoz Ag Stable composition comprising a high protein concentration
AU2024265540A1 (en) 2023-05-01 2025-10-30 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
KR20240170605A (ko) 2023-05-23 2024-12-04 연세대학교 산학협력단 신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이를 포함하는 비강 분무 제형
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
WO2025075970A1 (en) 2023-10-02 2025-04-10 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
US20250179207A1 (en) 2023-11-30 2025-06-05 Genzyme Corporation Methods for treating digitally-identified cd20-related disorders
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
CN117924490B (zh) * 2023-12-22 2024-10-22 华润生物医药有限公司 抗il-4r抗体及其用途
WO2025166234A1 (en) * 2024-01-31 2025-08-07 Apogee Therapeutics, Inc. Methods of administering antibodies that bind interleukin 4 receptor alpha
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
EP4623903A1 (en) 2024-03-28 2025-10-01 Fresenius Kabi Deutschland GmbH Pharmaceutical composition comprising dupilumab
WO2025221640A1 (en) 2024-04-15 2025-10-23 Sanofi Biotechnology Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
AU665763B2 (en) * 1991-05-03 1996-01-18 Seragen, Inc. Interleukin receptor targeted molecules for treatment of inflammatory arthritis
ATE171472T1 (de) * 1992-02-19 1998-10-15 Schering Corp Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ZA946875B (en) * 1993-09-07 1995-07-06 Smithkline Beecham Corp Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US6387632B2 (en) * 1998-06-11 2002-05-14 Hitachi, Ltd. Polynucleotide separation method and apparatus therefor
ATE326239T1 (de) 1998-09-18 2006-06-15 Dynavax Tech Corp Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
ES2382891T3 (es) 2000-05-26 2012-06-14 Immunex Corporation Uso de anticuerpos IL-4R y sus composiciones
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
DE60130466T2 (de) 2000-07-26 2008-06-12 Hououdou Co. Ltd. Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
RU2283665C2 (ru) 2000-12-22 2006-09-20 Сосьете Де Продюи Нестле С.А. Индуцирование толерантности
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
BR0117009A (pt) 2001-05-11 2004-04-20 Novartis Ag Composiçoes para utilização no tratamento de distúrbios associados a ige
US20050074462A1 (en) 2001-05-23 2005-04-07 Duotol Ab Supression of allergic reactions by transdermal administration of allergens conjugated to cholera toxin or fragments thereof
EP2298717B1 (en) 2001-11-30 2015-10-28 Biogen MA Inc. Antibodies against monocyte chemotactic proteins
JP2005530490A (ja) 2002-03-29 2005-10-13 シェーリング　コーポレイション インターロイキン−５に対するヒトモノクローナル抗体および方法およびこれを含む組成物
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
PT2000481E (pt) 2003-02-01 2016-06-17 Tanox Inc Anticorpos anti-ige humana de alta afinidade
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
CA2550933A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
DE602005006758D1 (de) 2004-02-27 2008-06-26 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
PE20060560A1 (es) * 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2007085815A2 (en) 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
SI2041177T1 (sl) 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2769992B1 (en) * 2006-10-02 2020-12-30 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
TWI464178B (zh) 2007-03-22 2014-12-11 Genentech Inc 細胞凋亡抗-ｉｇｅ抗體
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CN104788563A (zh) 2007-12-21 2015-07-22 米迪缪尼有限公司 白介素-4受体α(IL-4Rα)-173的结合成员
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US20110301046A1 (en) 2008-12-01 2011-12-08 Children's Hospital Medical Center Methods of Determining Efficacy of Glucocorticoid Treatment of Eosinophilic Esophagitis
EP2414520A2 (en) 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
WO2011026966A2 (en) 2009-09-07 2011-03-10 Dbv Technologies Method of treating eosinophilic esophagitis
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
WO2011163614A2 (en) 2010-06-24 2011-12-29 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
WO2012047954A1 (en) * 2010-10-06 2012-04-12 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
US20130324435A1 (en) 2011-01-06 2013-12-05 Children's Hospital Medical Center Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
EP2723899B1 (en) 2011-06-21 2020-11-18 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
EP2763683A1 (en) 2011-10-06 2014-08-13 N.V. Nutricia Treatment of eosinophilic esophagitis
CA2859284A1 (en) 2011-12-16 2013-06-20 Atopix Therapeutics Limited Combination of a crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
JP2015506950A (ja) 2012-01-31 2015-03-05 ジェネンテック， インコーポレイテッド 抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
ES2701093T3 (es) 2012-08-21 2019-02-20 Sanofi Biotechnology Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
NZ731864A (en) 2012-09-07 2022-07-01 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2014059178A1 (en) 2012-10-10 2014-04-17 Rhode Island Hospital Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis
JP2016507523A (ja) 2013-02-05 2016-03-10 エンクマフ アーゲー ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
SI3010539T1 (sl) * 2013-06-21 2019-11-29 Regeneron Pharma Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
EP4353254A3 (en) 2014-02-28 2024-07-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
MX2017006286A (es) 2014-11-14 2018-01-23 Sanofi Biotechnology Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
CA3014202A1 (en) 2016-02-19 2017-08-24 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
MX2019002344A (es) 2016-09-01 2019-09-06 Regeneron Pharma Metodos de prevenir o tratar la alergia administrando un antagonista de il-4r.
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
RU2759630C2 (ru) 2016-09-22 2021-11-16 Ридженерон Фармасьютикалз, Инк. Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
CA3052779A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
JP7315545B2 (ja) 2017-10-30 2023-07-26 サノフィ・バイオテクノロジー Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
BR112020020387A2 (pt) 2018-05-13 2021-01-19 Regeneron Pharmaceuticals, Inc. Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
WO2021026203A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
US12090201B2 (en) 2019-08-05 2024-09-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody
EP4073810A1 (en) 2019-12-09 2022-10-19 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CN115427450A (zh) 2020-03-27 2022-12-02 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
US20250154267A2 (en) 2020-05-22 2025-05-15 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
CA3204515A1 (en) 2021-01-08 2022-07-14 Jamie M. Orengo Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist

Also Published As

Publication number Publication date
JP2016041069A (ja) 2016-03-31
US8075887B2 (en) 2011-12-13
PT3064511T (pt) 2018-07-17
CN106267190A (zh) 2017-01-04
BRPI0919853B8 (pt) 2021-05-25
NO2018009I2 (no) 2019-01-30
US20140271681A1 (en) 2014-09-18
SI3064511T1 (en) 2018-08-31
FR18C1011I1 (enExample) 2018-04-27
SI3715372T1 (sl) 2024-05-31
TWI538686B (zh) 2016-06-21
MX356882B (es) 2018-06-19
DK3715372T3 (da) 2024-03-11
JP6449125B2 (ja) 2019-01-09
RU2014147773A (ru) 2016-06-20
US12162943B2 (en) 2024-12-10
CO6362024A2 (es) 2012-01-20
CN106267190B (zh) 2021-01-26
NL300922I2 (nl) 2019-01-15
PT3715372T (pt) 2024-03-14
US7608693B2 (en) 2009-10-27
MA32802B1 (fr) 2011-11-01
US8735095B2 (en) 2014-05-27
NO2018009I1 (no) 2018-03-06
EP2511300A3 (en) 2012-11-07
HUS1800014I1 (hu) 2018-03-28
JP2024040526A (ja) 2024-03-25
MY152448A (en) 2014-09-30
HK1159136A1 (en) 2012-07-27
SV2011003880A (es) 2011-08-15
RS65385B1 (sr) 2024-04-30
ES2404206T3 (es) 2013-05-24
CY2018003I1 (el) 2018-09-05
EP2636685A1 (en) 2013-09-11
US8337839B2 (en) 2012-12-25
PL3351560T3 (pl) 2020-09-21
TWI658833B (zh) 2019-05-11
CL2009002004A1 (es) 2010-03-05
RU2539774C2 (ru) 2015-01-27
CY2018003I2 (el) 2018-09-05
JP5291802B2 (ja) 2013-09-18
EP3064511A1 (en) 2016-09-07
NI201100064A (es) 2011-11-02
DK2356151T3 (da) 2013-06-17
LTC2356151I2 (lt) 2019-04-10
MX2011003346A (es) 2011-04-21
JP2013223495A (ja) 2013-10-31
ES2975006T3 (es) 2024-07-02
SI2356151T1 (sl) 2013-07-31
PE20100738A1 (es) 2010-11-03
AR073978A1 (es) 2010-12-15
IL211726A (en) 2015-10-29
JP7100731B2 (ja) 2022-07-13
CY1114123T1 (el) 2016-07-27
ES2802241T3 (es) 2021-01-18
PT3351560T (pt) 2020-05-11
PT2356151E (pt) 2013-05-07
EP3715372A1 (en) 2020-09-30
JP2022160404A (ja) 2022-10-19
HRP20240492T1 (hr) 2024-07-05
IL211726A0 (en) 2011-06-30
JP6843208B2 (ja) 2021-03-17
US20130078675A1 (en) 2013-03-28
BRPI0919853A2 (pt) 2016-03-15
RS57522B1 (sr) 2018-10-31
US20100047254A1 (en) 2010-02-25
EP2356151A1 (en) 2011-08-17
HRP20130467T1 (en) 2013-06-30
RS52782B (sr) 2013-10-31
CN103739711B (zh) 2016-09-14
ES2675917T3 (es) 2018-07-13
EP4345111A2 (en) 2024-04-03
PA8847001A1 (es) 2010-05-26
JP7442581B2 (ja) 2024-03-04
PH12014500462A1 (en) 2015-06-01
NZ596093A (en) 2012-11-30
TW201615216A (zh) 2016-05-01
EP2511300A2 (en) 2012-10-17
MX388436B (es) 2025-03-20
HN2011001210A (es) 2013-10-22
JO2865B1 (en) 2015-03-15
TW201029664A (en) 2010-08-16
HUE066473T2 (hu) 2024-08-28
JP5844772B2 (ja) 2016-01-20
US20090074793A1 (en) 2009-03-19
ECSP11011010A (es) 2011-06-30
RU2539774C3 (ru) 2020-11-06
AU2009311496B2 (en) 2014-05-29
SMT201800362T1 (it) 2018-09-13
PL2356151T3 (pl) 2013-08-30
AU2009311496B9 (en) 2014-10-30
US20210163611A1 (en) 2021-06-03
US20120052072A1 (en) 2012-03-01
UA102122C2 (ru) 2013-06-10
CA2737044C (en) 2017-02-28
EP4345111A3 (en) 2024-05-22
DK3064511T3 (en) 2018-07-16
AU2009311496A1 (en) 2010-05-14
RU2663106C2 (ru) 2018-08-01
CA2737044A1 (en) 2010-05-14
JP2019055963A (ja) 2019-04-11
SMT201300074B (it) 2013-09-06
HUE039212T2 (hu) 2018-12-28
ZA201101867B (en) 2012-08-29
EP3064511B1 (en) 2018-04-18
DK3715372T5 (da) 2024-08-26
EP2356151B1 (en) 2013-04-10
JP2021087440A (ja) 2021-06-10
TW201919700A (zh) 2019-06-01
JP2012507294A (ja) 2012-03-29
LT3064511T (lt) 2018-07-10
WO2010053751A1 (en) 2010-05-14
EP3351560A1 (en) 2018-07-25
FI3715372T3 (fi) 2024-03-18
CN102197052B (zh) 2014-02-12
RU2011120194A (ru) 2012-12-10
LUC00059I1 (enExample) 2018-01-03
UY32213A (es) 2010-05-31
LT3715372T (lt) 2024-03-25
LTPA2018002I1 (lt) 2018-02-12
CN102197052A (zh) 2011-09-21
HK1250733A1 (en) 2019-01-11
LUC00059I2 (enExample) 2018-03-28
PL3715372T3 (pl) 2024-06-24
KR20110074980A (ko) 2011-07-05
PL3064511T3 (pl) 2018-09-28
CY1122092T1 (el) 2020-07-31
CN103739711A (zh) 2014-04-23
BRPI0919853B1 (pt) 2020-10-27
HRP20181148T1 (hr) 2018-09-21
JP6608505B2 (ja) 2019-11-20
NO2023019I1 (no) 2023-05-02
US20180179288A1 (en) 2018-06-28
JP2020007378A (ja) 2020-01-16
CR20110148A (es) 2011-04-27
EP3715372B1 (en) 2024-01-24
EP3351560B1 (en) 2020-04-22
KR101599706B1 (ko) 2016-03-04
FR18C1011I2 (fr) 2020-03-06

Similar Documents

Publication Publication Date Title
US12162943B2 (en) High affinity human antibodies to human IL-4 receptor
NZ576040A (en) High affinity human antibodies to human il-4 receptor
AU2014216019B2 (en) High affinity human antibodies to Human IL-4 receptor
US20250197516A1 (en) High affinity human antibodies to human il-4 receptor
HK40102995A (en) High affinity human antibodies to human il-4 receptor
HK40036835B (en) High affinity human antibodies to human il-4 receptor
HK40036835A (en) High affinity human antibodies to human il-4 receptor
HK1250733B (en) Medical use of high affinity human antibodies to human il-4 receptor
HK1228425A1 (en) Medical use of high affinity human antibodies to human il-4 receptor
HK1228425B (en) Medical use of high affinity human antibodies to human il-4 receptor
HK1189600A (en) High affinity human antibodies to human il-4 receptor
HK1159136B (en) High affinity human antibodies to human il-4 receptor

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 OCT 2016 BY COMPUTER PACKAGES INC

Effective date: 20131026

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2017 BY ANAQUA SERVICES

Effective date: 20160922

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2018 BY ANAQUA SERVICES

Effective date: 20170920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2019 BY ANAQUA SERVICES

Effective date: 20180919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2020 BY ANAQUA SERVICES

Effective date: 20190918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2021 BY ANAQUA SERVICES

Effective date: 20200917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2022 BY ANAQUA SERVICES

Effective date: 20210921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2023 BY ANAQUA SERVICES

Effective date: 20220922

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2024 BY ANAQUA SERVICES

Effective date: 20230921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2025 BY ANAQUA SERVICES

Effective date: 20240920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2026 BY ANAQUA SERVICES

Effective date: 20250924